The estimated Net Worth of Bros. Advisors Lp667, L.P.B... is at least 9.89 十億$ dollars as of 30 November 2021. Bros B owns over 394,895 units of Seagen Inc stock worth over 9,828,965,765$ and over the last 3 years Bros sold SGEN stock worth over 63,396,443$.
Bros has made over 1 trades of the Seagen Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Bros sold 394,895 units of SGEN stock worth 63,396,443$ on 30 November 2021.
The largest trade Bros's ever made was selling 394,895 units of Seagen Inc stock on 30 November 2021 worth over 63,396,443$. On average, Bros trades about 394,895 units every 0 days since 2021. As of 30 November 2021 Bros still owns at least 42,947,504 units of Seagen Inc stock.
You can see the complete history of Bros B stock trades at the bottom of the page.
Over the last 22 years, insiders at Seagen Inc have traded over 729,924,224$ worth of Seagen Inc stock and bought 35,347,908 units worth 1,433,871,526$ . The most active insiders traders include Bros. Advisors Lp667, L.P.B...、Felixbaker Julian Baker Bro...、Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of 18,157,295$. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth 2,262,166$.
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
Seagen Inc executives and other stock owners filed with the SEC include: